MediWound Projects Strong Revenue Growth Through 2028, Provides Positive Clinical & Operational Updates
MDWD sits 36% above its 52-week low of $14.14.
Summary
MediWound provided a corporate update and financial outlook, projecting significant revenue growth through 2028, alongside positive clinical progress for EscharEx and operational advancements for NexoBrid. The company also reported a strong cash position of $54 million with no debt.
Key Events · Earnings and Guidance · MDWD
-
Strong Revenue Guidance
Updated financial outlook projects revenue growth from $17 million in 2025 to $24–26 million in 2026, $32–35 million in 2027, and $50–55 million by 2028.
-
EscharEx Clinical Progress
Interim assessment and enrollment completion for the VALUE Phase III trial in venous leg ulcers (VLUs) are expected by year-end 2026, with plans to initiate a Phase II study in diabetic foot ulcers (DFUs) and an investigator-initiated trial (IIT) for pressure ulcers (PUs) in 2026.
-
NexoBrid Operational Expansion
The expanded NexoBrid manufacturing facility is now fully operational, increasing production capacity sixfold, with regulatory approvals targeted for 2026.
-
Healthy Balance Sheet
The company reported a cash position of $54 million as of December 31, 2025, with no outstanding debt.
Analysis · MDWD · Life Sciences
MediWound's corporate update and financial outlook ahead of the J.P. Morgan Healthcare Conference present a highly positive trajectory for the company. The updated revenue guidance, projecting a substantial increase from $17 million in 2025 to $50-55 million by 2028, signals strong anticipated growth driven by its product pipeline. This long-term outlook, coupled with a healthy cash position of $54 million and no debt, provides a solid financial foundation. Furthermore, the progress in the EscharEx Phase III trial and plans for expansion into additional chronic wound indications, alongside the operational readiness of the expanded NexoBrid manufacturing facility, underscore significant advancements in its core product development and commercialization efforts. Investors should view this comprehensive update as a strong indicator of future potential and operational execution.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MDWD was trading at $19.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $247.5M. The 52-week trading range was $14.14 to $22.51. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.